The virus's behavior is shifting in ways that demand urgent attention.
En los laboratorios de Santiago, un equipo de inmunólogos lleva cinco años construyendo una respuesta preventiva contra el hantavirus Andes, un patógeno sin cura que mata a una fracción significativa de quienes infecta. La ciencia está validada, la plataforma tecnológica ya protege a millones de lactantes en el mundo, y Chile posee tanto la infraestructura como la experiencia clínica para avanzar. Lo que separa a este país de una vacuna disponible antes de 2030 no es el conocimiento, sino la voluntad política y el financiamiento que aún no llegan.
- El hantavirus Andes no tiene cura una vez que se instala, y en 2019 se documentó transmisión de persona a persona —un evento que un reciente brote en un buque polar sugiere podría estar repitiéndose.
- Con 38 casos registrados en 2026 y picos históricos de 90, la carga de enfermedad fluctúa de forma impredecible mientras el cambio climático amenaza con expandir el roedor portador hacia regiones mineras y agrícolas del norte.
- El equipo del Instituto Milenio de Inmunología ya validó el diseño de la vacuna y tiene identificado un laboratorio con certificación GMP en Chile capaz de escalar la producción hasta ensayos humanos.
- La misma plataforma tecnológica protege hoy a millones de lactantes en el mundo, y los investigadores chilenos lideraron estudios clínicos de una de las vacunas más usadas contra el SARS-CoV-2 —la capacidad está demostrada.
- El turismo representa cerca del tres por ciento del PIB chileno y expone a visitantes y trabajadores de campo a un virus presente desde el Atacama hasta la Patagonia; sin financiamiento, ese riesgo permanece sin respuesta.
En un laboratorio de Santiago, un equipo de inmunólogos lleva cinco años desarrollando una vacuna preventiva contra el hantavirus Andes, patógeno endémico de Chile y Argentina que infecta a decenas de personas cada año y mata a una proporción significativa de ellas. La ciencia es sólida. Lo que falta es dinero y voluntad política.
El Dr. Alexis Kalergis, director del Instituto Milenio de Inmunología e Inmunoterapia de la Universidad Católica, enmarca el proyecto como una cuestión de estrategia económica y geográfica, no solo de salud pública. Chile registró 38 casos en 2026, con picos históricos de 90 en 2017 y 70 en 2019. Ese mismo año se documentó el último caso de transmisión entre personas —hasta que un reciente brote en un buque de investigación polar sugirió que el comportamiento del virus podría estar cambiando.
La vacuna es profiláctica: entrena al sistema inmune antes de la exposición. La plataforma tecnológica que la sustenta no es experimental; es la misma que hoy protege a millones de lactantes en el mundo. El Dr. Pablo González señala que el equipo ya validó el diseño y tiene identificado un laboratorio con certificación GMP en Chile capaz de escalar la producción desde la fase preclínica hasta los ensayos humanos.
Kalergis subraya que la importancia de la vacuna va mucho más allá del conteo anual de casos. El turismo representa cerca del tres por ciento del PIB chileno y lleva a visitantes internacionales a entornos naturales donde el roedor portador tiene presencia documentada desde el Atacama hasta el extremo sur. Trabajadores forestales, mineros y agrícolas enfrentan exposición ocupacional en zonas de circulación viral.
El cambio climático añade otra capa de urgencia: si las condiciones ambientales desplazan hacia el norte la población de roedores infectados, sectores mineros y agrícolas hoy fuera del rango del virus quedarían expuestos a una amenaza que aún no anticipan. Los investigadores estiman que con financiamiento adecuado los ensayos clínicos en humanos podrían comenzar pronto, con una vacuna disponible antes de que termine la década. Durante la pandemia de COVID-19, científicos chilenos lideraron estudios clínicos de una de las vacunas más utilizadas contra el SARS-CoV-2. La infraestructura y la experiencia existen. Solo falta la decisión de financiar.
In a laboratory in Santiago, a team of immunologists has spent the last five years building something that could reshape how Chile protects itself against a virus that has no cure once it takes hold. They are working on a vaccine against hantavirus Andes, a pathogen endemic to Chile and Argentina that infects dozens of people each year and kills a significant portion of those it infects. The work is advancing. The science is solid. What they need now is money and political will.
Dr. Alexis Kalergis, who directs the Millennium Institute for Immunology and Immunotherapy at the Catholic University, frames the project not as a response to routine disease burden but as a matter of economic and geographic strategy. This year, Chile has recorded 38 cases of hantavirus infection. In 2017, the country saw 90. In 2019, 70. The numbers fluctuate in a pattern that researchers have come to recognize, but what changed in 2019 was the nature of transmission itself. That year marked the last documented case of person-to-person spread—until a recent outbreak aboard a polar research vessel suggested the virus's behavior might be shifting in ways that demand urgent attention.
The vaccine being developed is prophylactic, meaning it trains the immune system before exposure rather than fighting the virus after infection has begun. The research team has spent more than two decades refining the platform technology underlying this approach, testing it against other viruses and publishing results in high-impact international journals. The platform itself is not experimental. It is the same technology currently protecting millions of infants worldwide. Dr. Pablo González, a researcher at the institute and academic at the Catholic University, explains that the team has already validated a vaccine design and identified a GMP-certified laboratory in Chile capable of scaling production from preclinical work through human trials.
Kalergis emphasizes that the vaccine's importance extends far beyond the annual case count. Tourism represents roughly three percent of Chile's GDP and draws international visitors to natural environments, cabins, and work territories across a vast geography where the virus-carrying rodent has documented presence from the Atacama Desert to the southern tip of the country. Field workers in forestry, mining, and agriculture face occupational exposure in regions where the virus circulates. A vaccine could meaningfully reduce infection risk for these populations.
Climate change introduces a second dimension of urgency. The rodent that carries hantavirus has potential distribution across nearly the entire country, but current cases concentrate between Valparaíso and Aysén because viral density in the animal population is highest there. If environmental conditions shift and the infected rodent population expands northward, mining and agricultural sectors currently outside the virus's range would face a threat they do not now anticipate. The vaccine becomes not just a response to present risk but a hedge against future geography.
The researchers estimate that with adequate funding and policy support, human clinical trials could begin within a defined timeframe. A vaccine available before the end of the decade is, they believe, an achievable goal. The team's track record supports this confidence. During the COVID-19 pandemic, Chilean scientists led clinical studies for one of the most widely used vaccines against SARS-CoV-2 globally. They have conducted trials for influenza vaccines and respiratory syncytial virus vaccines. The infrastructure exists. The expertise exists. What remains is the decision to fund it.
Notable Quotes
This vaccine could serve field workers in forestry and tourism, as well as tourists, in minimizing the risk of infection and disease.— Dr. Alexis Kalergis, director of the Millennium Institute for Immunology and Immunotherapy
With adequate funding and policy support, human clinical trials could begin within a defined timeframe, and a vaccine available before the end of the decade is an achievable goal.— Chilean research team at the Millennium Institute for Immunology and Immunotherapy
The Hearth Conversation Another angle on the story
Why does a vaccine against a virus that causes fewer than 40 cases a year warrant this level of investment and urgency?
Because those numbers don't capture the real risk. The virus is endemic. It's not going away. And the pattern of transmission is changing—we saw person-to-person spread in 2019, then a cluster on a research vessel. That suggests the virus's behavior is less predictable than we thought.
But the cases are concentrated in one region. Why would mining companies in the north care?
They don't care yet because the virus isn't there yet. But climate change is shifting where the rodents live. In five or ten years, the virus could be present in regions where it's never been documented. By then, it's too late to develop a vaccine.
So this is really about prevention before the problem arrives.
Exactly. It's cheaper and smarter to vaccinate people before exposure than to manage outbreaks after they happen. And the technology already works—we use it in millions of infants every year for other diseases.
What's the actual barrier right now?
Money and political attention. The science is ready. The lab infrastructure is ready. We just need someone to decide this matters enough to fund it.
And if they do?
Human trials could start soon. A vaccine available by 2030 is realistic. That's the window before climate change potentially expands the virus's range.